Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Move comes amid rising regulatory pressures
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
The license is valid for five years, effective from April 9, 2026
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Subscribe To Our Newsletter & Stay Updated
